The DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years
Open accessAbstract
Human respiratory syncytial virus (RSV) is a ubiquitous pathogen that infects everyone worldwide early in life and is a leading cause of severe lower respiratory tract disease in the pediatric population as well as in the elderly and in profoundly immunosuppressed individuals. RSV is an enveloped, nonsegmented negative-sense RNA virus that is classified in Family Paramyxoviridae and is one of its more complex members. Although the replicative cycle of RSV follows the general pattern of the Paramyxoviridae, it encodes additional proteins. Two of these (NS1 and NS2) inhibit the host type I and type III interferon (IFN) responses, among other functions, and another gene encodes two novel RNA synthesis factors (M2-1 and M2-2). The attachment (G) glycoprotein also exhibits unusual features, such as high sequence variability, extensive glycosylation, cytokine mimicry, and a shed form that helps the virus evade neutralizing antibodies. RSV is notable for being able to efficiently infect early in life, with the peak of hospitalization at 2–3 months of age. It also is notable for the ability to reinfect symptomatically throughout life without need for significant antigenic change, although immunity from prior infection reduces disease. It is widely thought that re-infection is due to an ability of RSV to inhibit or subvert the host immune response. Mechanisms of viral pathogenesis remain controversial. RSV is notable for a historic, tragic pediatric vaccine failure involving a formalin-inactivated virus preparation that was evaluated in the 1960’s and that was poorly protective and paradoxically primed for enhanced RSV disease. RSV also is notable for the development of a successful strategy for passive immunoprophylaxis of high-risk infants using RSV-neutralizing antibodies. Vaccines and new antiviral drugs are in pre-clinical and clinical development, but controlling RSV remains a formidable challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773
The Burden of Respiratory Syncytial Virus Infection in Young Children
Hall, C. B., Weinberg, G. A., Iwane, M. K., Blumkin, A. K., Edwards, K. M., Staat, M. A., Auinger, P., Griffin, M. R., Poehling, K. A., Erdman, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804877 · Cited by 2,246
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C., & Walsh, E. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043951 · Cited by 2,226
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus
Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A., Walsh, E. E., Freeman, M. W., Golenbock, D. T., Anderson, L. J., et al. (2000) · Nature Immunology · doi:10.1038/80833 · Cited by 1,683
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
Stein, R. T., Sherrill, D., Morgan, W. J., Holberg, C. J., Halonen, M., Taussig, L. M., Wright, A. L., & Martinez, F. D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10321-5 · Cited by 1,633
Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus
Glezen, W. P. (1986) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1986.02140200053026 · Cited by 1,527
Innate immunity of the newborn: basic mechanisms and clinical correlates
Levy, O. (2007) · Nature Reviews Immunology · doi:10.1038/nri2075 · Cited by 1,223
Cited by
Viral Bronchiolitis in Children
Meissner, H. C. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1413456 · Cited by 714
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Interferon-Lambda: A New Addition to an Old Family
Donnelly, R. P., & Kotenko, S. V. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0078 · Cited by 420
Antunes, K. H., Fachi, J. L., de Paula, R., da Silva, E. F., Pral, L. P., dos Santos, A. Á., Dias, G. B. M., Vargas, J. E., Puga, R., Mayer, F. Q., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11152-6 · Cited by 385
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383
Metadata
- Authors
- Collins, P. L., & Melero, J. A.
- Venue
- Virus Research
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 162
- Issue
- 1-2
- Pages
- 80-99
- ISSN
- 0168-1702 (ISSN-L)
- OpenAlex
- W1989959574
- Cited by
- 455
- References
- 264
- FWCI
- 26.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. https://app.cochat.ai/papers/10.1016/j.virusres.2011.09.020
- The paper
- Collins, P. L., & Melero, J. A. (2011). Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. Virus Research. https://doi.org/10.1016/j.virusres.2011.09.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.